News & Events


Recent Firm Activities and Highlights

COTA Collaborates with Novartis Pharmaceuticals Corporation
03.27.17
Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most. Read More
BMP Portfolio company Bivarus Raises $4 Million to Fuel Continued Growth
03.22.17
Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience and employee engagement, announced today it raised $4 million in a Series B from existing investors. Hatteras Venture Partnersled this latest financing round. Other participants in the round include Excelerate Health Ventures, Nashville-based NueCura Partners and Boston Millennia Partners. Read More
Growth continues for Odyssey; move within Matrix planned
02.28.17
It was a year of growth in 2016 for Odyssey Logistics & Technology Corp. as it announced net revenue increased by 8 percent. In other words, 2016 was a typical year for the Danbury-based transportation company. Odyssey officials said the company has now experienced growth for 14 consecutive years. A major acquisition, maintaining a leadership position in key markets and expanding into new areas helped spur last year’s growth, Robert Shellman, president and CEO, said.... Read More
Why Big Health Insurance is pouring money into startups
03.21.17
One effect of the Affordable Care Act, a.k.a. Obamacare? A spike in venture interest in health care startups. Digital health care companies raised $2.3 billion in the first half of 2014, which surpasses the total raised in all of 2013, according Rock Health, a health care-focused seed fund. That figure is impressive given that 2013 was already a record year at $1.9 billion raised. (That's a 39% increase year over year, even as biotech investment grew just 8% and medical devices investment fell by 17%.) Read More
New AI Tool Improves Cognitive Testing
03.09.17
One good piece of news in recent years is that people around the world are living longer. The less good news is that older age exposes more of us to varieties of cognitive decline, including Alzheimer’s disease. According to the Alzheimer’s Association, the number of people with this diagnosis is likely to grow from around five million today to some 13.5 million in 2050. What could help stem this tsunami of pending illness? A team from MIT and Lahey Hospital and Medical Center has created a tool that will make it easier to detect cognitive impairment, enabling treatment to begin earlier and, potentially, improve outcomes. Read More
Introducing Cota OCM™—A Solution for Practices Moving to Value-based Programs
02.10.17
Over the last year, our team at Cota has worked closely with providers and CMS—preparing for the eventual move to value-based payment under MACRA by studying the complexities of the law and building an OCM-specific technology solution on top of our CNA Guided Care™ platform. To address the obvious policy question up front: While the new administration has already planned or implemented sweeping changes across other areas, all indications (including these comments from former CMS head Andy Slavitt) point to Alternative Payment Models (APMs) and value-based payments sticking around for the long haul. In this post, we want to share what we’ve learned so far and officially announce Cota’s new technology solution specifically designed to help providers address the challenges and opportunities during this exciting time in the move value-based healthcare. Jump straight to the Cota OCM product announcement here. Read More
Looking Inside the Founder Forum: Dan Mingle of Mingle Analytics
01.11.17
Dan Mingle, as you’ll learn below, never thought of himself as an entrepreneur. He was just a doctor who while running his own physician practice in Norway, Maine, for more than a decade recognized a need for a more efficient healthcare system. Instead of being content with the lack of a solution, he saw an opportunity to execute on his ideas and play a part in improving the healthcare system and helping physicians like himself. Read More
Philips and Illumina join forces to offer integrated genomics solutions for oncology
01.10.17
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Illumina, Inc.(NASDAQ:ILMN), the global leader in DNA sequencing and array-based technologies, today announced a strategic collaboration, that aims to integrate Illumina’s sequencing systems for large-scale analysis of genetic variation and function and Philips’ IntelliSpace Genomics clinical informatics platform, and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the US who want to develop precision medicine programs in oncology. Read More
PAREXEL Releases Consulting Regulatory Portal
01.10.17
Today's Challenge Problems will always arise, and establishing a right-first-time (RFT) environment is a one-time investment to deal with this inevitability. - See more at: https://www.parexel.com/regulatoryportal?utm_source=HBRprintedURL&utm_medium=print&utm_campaign=regulatoryhub#sthash.pG36KtGB.dpuf Read More
Season’s Greetings from BMP
12.19.16
We wish you a very happy, healthy and safe holiday season! Read More
Odyssey Logistics & Technology Posts Eight Percent Growth; Continues fourteen year trend of consecutive growth
02.02.17
Danbury, Conn. (Feb. 2, 2017) — Odyssey Logistics & Technology Corporation (Odyssey) announced today that it has posted fourteen consecutive years of growth, with net revenue up eight percent in 2016. The company attributes this year’s results to sustaining its leadership position in complex key markets, implementing operational efficiencies and maximizing benefits from the acquisition of Linden Bulk Transportation. Read Full Release
BMP Invests in COTA
12.20.16
Boston Millennia Partners Invests in Cota, Inc. Boston, MA, December 2016, Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare. Read Full Release
Jeffries Key Takeaway: Another Formulary Win Further Positions Xtampza for a Potential 1H17 Inflection
12.15.16
COLL announced another formulary “win” for Xtampza following successful contracting with ESRX, the largest US pharmacy benefits manager (PBM). Starting January 1, 2017, Xtampza will be added to ESRX’s formulary as a preferred brand with access to another 28M commercial lives. Based on steady progress with the launch and managed care wins, we continue to believe that Xtampza Rxs are positioned for an inflection in 1H17 and see the drug as a $400M+ peak product. Read Full Release
Report of the Cancer Moonshot Task Force
10.17.16
While bold, the goal of the Cancer Moonshot is within our grasp. Today, society has the benefit of decades of scientific understanding and vast amounts of rich data just waiting to be transformed into solutions. We now know that cancer is hundreds of diseases, largely of our genome, and we have developed new and innovative ways of capitalizing on this knowledge. We know that our behavior and environment contribute to our likelihood of getting cancer, and we are modifying our behaviors and exposures to avoid known risks. We know that prevention and early diagnosis are key to fighting cancer, and we can build these efforts into clinical care. Read Full Release
MedAptus Hospitalist Customers Leverage Real-Time Data to Manage Patient Risk
10.20.16
MedAptus® today announced the availability of real-time analytics, the Hospitalist Risk Series, that leverage patient history and admission activity to identify those at greatest risk for re-admissions, and also helps providers better manage resources related to length of stay. The new Series, aimed primarily at hospitalists on the front line of acute patient care, is available through the MedAptus Professional Charge Capture (Pro) suite. This latest offering extends the Pro solution’s ability to compute data from admission/discharge feeds and diagnosis history in order to meaningfully impact key metrics around hospitalizations that hospital medicine providers are increasingly responsible for. Read Full Release
Despite Recent Performance We Still See Room for Upside Given United Win and Xtampza ER Tailwinds for 2017
10.03.16
Following recent share performance that has shares almost doubling in the past two weeks, we continue to see room for share appreciation as the Xtampza ER launch has clear tailwinds as we exit the summer through 2017. Management has signed at least one large managed care win with UnitedHealth (UNH $140.00) and we believe additional managed care wins are likely during the fourth quarter as well as the potential for comparative data between OxyContin and Xtampza ER being added to label. Admittedly, the Xtampza ER launch was slow as management chose to launch during the summer months despite the historically slow season, which was compounded by a lack of approved marketing materials. However, the company recently received approved marketing materials and given formulary wins (both UnitedHealth and likely additional wins), we should see a ramping up of scripts over the next quarter and into 2017. Read Full Release
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
09.29.16
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology. The publication presents the results from a human abuse potential (HAP) study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza® ER (oxycodone extended-release), oral administration of chewed Xtampza ER, and oral administration of crushed immediate-release oxycodone in non-dependent, recreational drug abusers. Read Full Release
Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year
06.27.16
CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of the Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Winners were selected by an independent panel of judges, and the award was presented at a special gala event at the Marriott Copley Place on June 23, 2016. Read Full Release
Collegium Receives FDA Approval for Xtampza™ ER
04.26.16
CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza™ ER (oxycodone) extended-release (ER) capsules CII, a twice-daily, oxycodone medication for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Read Full Release
Bivarus Raises $2 Million to Fuel Expansion Following Strong Growth in 2015
03.19.16
DURHAM, N.C. (Business Wire) March, 2016 – Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience, announced today it raised $2 million in its oversubscribed round of funding. This latest financing was co-led by new investor Hatteras Venture Partners and existing investor Excelerate Health Ventures. In addition to local investors, Bivarus attracted new institutional investors from outside of the Raleigh/Durham region: NueCura Partners of Nashville, Tenn., and Boston Millennia Partners of Boston, Mass. Read Full Release
Dana Callow to be Panelist at Funding Models in Biotech MBBP Life Sciences Series – Panel 3
09.22.16
Today’s financing environment for emerging biotech companies presents a number of challenges. Venture capital funds are ever more cautious about taking risk, and some players have departed the field at the early stage. Government grants have also closed their spigots in recent years, as the volume of government funding has plummeted dramatically. However, new players have entered the fray in the last few years, including family offices, super angels, strategic partners and foreign investors, replacing the investment dollars previously offered by institutional investors. So where does an emerging biotech company forage for precious dollars? Come join us on September 22nd at the CIC in Cambridge to hear a panel of experts discuss these trends. At the event, you will discover, among other ideas: Where and how to find the new players; What areas of interest are these players financing; How to optimize your chances of success; What are deal structures looking like? Read Full Release
David Carney to Attend CED Tech Venture Conference
09.13.16
From early startups to growth-stage companies to highly successful businesses, the CED Tech Venture Conference reflects North Carolina’s vibrant entrepreneurial community and showcases many of the most-promising emerging companies in the region. Attendees will have the opportunity to connect with a diverse group of over 100 investors, from venture capital to corporate to angels, including funds such as Sequoia Capital, Greycroft, Grotech Ventures, and Comcast Ventures. Engage with industry leaders, radical thinkers and trail-blazing entrepreneurs, and learn about the disruptive innovations that are transforming the ways in which we live, work and play. Read Full Release
Dana Callow to be on Lifescience Panel at the Richi Immersion Summer 2016 Program
07.21.16
Richi Social Entrepreneurs is a Richi Foundation initiative whose mission is to foster and catalyze the development of international Social Entrepreneurship ecosystems, taking Boston's unique case as our role model. Richi Social Entrepreneurs Immersion Summer 2016 is a one-month eye-opening experience in Boston. Social Entrepreneurs have the opportunity to explore Boston's advanced Social Innovation ecosystems, while working on their social value proposition and problem-solution fit. Social Entrepreneurs wear different hats, from startup founders in BioTech, HealthCare or Education, to professionals working in IT, CleanTech or Finance. It's not the industry that determines a project's potential social impact, it's the drive and motivation of the entrepreneur behind the idea. Read Full Release
Dana Callow to Speak at Cancer Moonshot Summit
06.29.16
Boston Millennia Partners’ Dana Callow to Speak at Cancer Moonshot Summit. Simultaneous events will take place at the same time throughout the country to improve awareness of the program and gain support for funding research. Representatives from major pharmaceutical companies and service providers including Takeda, Syapse, and Foundation Medicine well as researchers from the area will speak about the Moonshot and their roles in finding a cure. The White House is sponsoring The National Cancer Moonshot summit. Vice President Joe Biden will speak on behalf of the program and subsequently there will be panel discussions by leading cancer specialists and patient advocates. As a Board Member of the National Leukemia Society Dana will address how non-profit organizations can positively impact the effort to find cures and improve patient care. Location: MGH Cancer Center, Lawrence House, 1st Floor Conference Room, 10 North Grove St., Boston MA Please contact liz@bmpvc.com for the speaker guide Read Full Release
PAREXEL Experts to Discuss Key Drug Development Insights at DIA 2016
06.20.16
BOSTON, June 20, 2016— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that several of its experts will discuss key issues facing the industry at the 52nd Annual Drug Information Association (DIA) meeting, held from June 26-30, 2016 in Philadelphia. Read Full Release
PAREXEL Announces Master Services Agreement with Pfizer
06.10.16
BOSTON, June 10, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has signed a services agreement with Pfizer Inc. Under the terms of this agreement, PAREXEL will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed. Read Full Release
PRXL to Present at Cambridge Healthtech Institute’s Twelfth Annual Biomarkers & Diagnostics World Congresss 2016
05.18.16
Presentation: Wednesday, May 18 - 9:20 am Extending Precision Medicine Beyond Oncology Arlene Hughes, Senior Director, Genomic Medicine, Clinical Research Services Visit PAREXEL at Booth 4 in the Exhibit Hall. Read Full Release
Odyssey Logistics & Technology (Odyssey) at World of Concrete Trade Show
02.02.15
Odyssey will have representatives from its business service, Web Integrated Network (WIN) at booth C4123. Visitors are welcome to stop by the booth to learn more about this web-based logistics management capability, and meet WIN team member, Phil Villapiano, former American football star and champion Read Full Release
Dana Callow to Speak on The State of The VC Market Panel
11.17.16
ACG Boston's regular networking breakfast returns to Serafina in Boston's financial district. Open to all, the Networking Breakfast is ACG Boston's signature event, where M&A professionals come to network and hear industry experts share their outlook, opinions, successes and failures. Join New England's M&A community on November 17 to hear a panel discussion on the current state of the VC market -- how the industry has evolved and where it's headed in the future. Read Full Release
BMP to attend 2016 SBIR New England Regional Summit
10.06.16
The 2016 New England Regional Innovation Summit is a two-day engagement opportunity being held at MIT, for technology innovators and entrepreneurs. This effort, spearheaded by the SBA Office of Investment and Innovation (OII), is a coordinated effort amongst participating SBIR/STTR agencies to continually engage, identify, and encourage participation in the SBIR/STTR programs. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, affectionately referred as America’s Seed Fund, play an instrumental role in providing early stage, non-dilutive, research and development capital which spurs small advanced technology firms’ innovations. Annually more than $2.5 billion non-diluted in early stage research and development funding is provided through these programs. Read Full Release
Dana Callow to be Panelist at Funding Models in Biotech MBBP Life Sciences Series – Panel 3
09.22.16
Today’s financing environment for emerging biotech companies presents a number of challenges. Venture capital funds are ever more cautious about taking risk, and some players have departed the field at the early stage. Government grants have also closed their spigots in recent years, as the volume of government funding has plummeted dramatically. However, new players have entered the fray in the last few years, including family offices, super angels, strategic partners and foreign investors, replacing the investment dollars previously offered by institutional investors. So where does an emerging biotech company forage for precious dollars? Come join us on September 22nd at the CIC in Cambridge to hear a panel of experts discuss these trends. At the event, you will discover, among other ideas: Where and how to find the new players; What areas of interest are these players financing; How to optimize your chances of success; What are deal structures looking like? Read Full Release
2016 Wells Fargo Healthcare Conference
09.07.16
Please join us on September 7-8 for the 11th Annual Wells Fargo Securities Healthcare Conference in Boston. Read Full Release
Dana Callow to be on Lifescience Panel at the Richi Immersion Summer 2016 Program
07.21.16
Richi Social Entrepreneurs is a Richi Foundation initiative whose mission is to foster and catalyze the development of international Social Entrepreneurship ecosystems, taking Boston's unique case as our role model. Richi Social Entrepreneurs Immersion Summer 2016 is a one-month eye-opening experience in Boston. Social Entrepreneurs have the opportunity to explore Boston's advanced Social Innovation ecosystems, while working on their social value proposition and problem-solution fit. Social Entrepreneurs wear different hats, from startup founders in BioTech, HealthCare or Education, to professionals working in IT, CleanTech or Finance. It's not the industry that determines a project's potential social impact, it's the drive and motivation of the entrepreneur behind the idea. Read Full Release
Dana Callow to Speak at Cancer Moonshot Summit
06.29.16
Boston Millennia Partners’ Dana Callow to Speak at Cancer Moonshot Summit. Simultaneous events will take place at the same time throughout the country to improve awareness of the program and gain support for funding research. Representatives from major pharmaceutical companies and service providers including Takeda, Syapse, and Foundation Medicine well as researchers from the area will speak about the Moonshot and their roles in finding a cure. The White House is sponsoring The National Cancer Moonshot summit. Vice President Joe Biden will speak on behalf of the program and subsequently there will be panel discussions by leading cancer specialists and patient advocates. As a Board Member of the National Leukemia Society Dana will address how non-profit organizations can positively impact the effort to find cures and improve patient care. Location: MGH Cancer Center, Lawrence House, 1st Floor Conference Room, 10 North Grove St., Boston MA Please contact liz@bmpvc.com for the speaker guide Read Full Release
DIA Annual Meeting
06.26.16
DIA 2016 52nd Annual Meeting Read Full Release
Xconomy’s EXOME Presents: What’s Hot in Boston Biotech
04.06.16
After an unprecedented multi-year bull run, biotech is facing headwinds once again. Drug companies have become a target in an election year, putting pricing strategies under a microscope. Valuations have tumbled, drying up a fertile ground for IPOs. Yet biotech innovation continues apace, particularly in Boston. Gene editing has taken the scientific world by storm, and may soon reach human clinical testing. New ways of harnessing the immune system to battle cancer are being unlocked. Investments in neuroscience, long a drug development minefield, have picked up. And local venture firms are armed with new funds to spend on startups. Read Full Release
Xconomy Forum: Robo Madness: The A.I. Explosion
03.31.16
Major advances are happening in robotics and the driving force behind it—artificial intelligence. Now companies of all sizes are using emerging A.I. technologies from deep learning to computer vision to natural language processing to build their businesses—and impact our daily lives. Think Google, Facebook, iRobot, and a whole new generation of startups: the technologies are already starting to transform retail, advertising, social media, transportation, connected homes, and other industries. Read Full Release
PAREXEL to Attend ASCO Annual Meeting in June 2016
06.03.16
PAREXEL to Attend ASCO Annual Meeting in June 2016 Read Full Release